Jaguar Health, Inc.
Close on Oct 19, 2026
- Market cap
- $2.28M
- P/E (TTM)
- –
- Dividend yield
- –
About Jaguar Health
Pharmaceutical Preparations, SIC 2834
The company operates in the pharmaceutical industry and focuses on developing and commercializing therapeutic products. Its business activities are organized into two primary operating segments: Human Health and Animal Health. The company develops and markets treatments such as Mytesi, Gelclair, Neonorm, and Canalevia. Key customers for its product offerings include specialized healthcare purchasers such as specialty pharmacies and pharmaceutical distributors.
Regarding its physical operations and footprint, the entity maintains leased corporate office premises, including facilities situated in the United States and Europe, alongside leased operational vehicles. The provided records identify business activities spanning the United States and Europe, supported by laboratory equipment, computer equipment, and leased office suites. The provided text contains tagged disclosures without stating a specific corporate headquarters city or address.
Summary of the business section of Jaguar Health's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Jaguar Health, Inc.
- Headquarters
- San Francisco, CA
- Address
- 200 Pine Street Suite 400 94104
- Phone
- (415) 371-8300
- Employees
- 47, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- RBSM LLP, Larkspur, California
Stock & identifiers
- Ticker
- JAGX
- Exchange
- Nasdaq
- IPO date
- May 14, 2015
- Shares outstanding
- 5M, Aug 14, 2026
- Public float
- $3.80M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-15 reverse, Sep 17, 2026; 1-for-35 reverse, Apr 30, 2026; 1-for-25 reverse, Mar 24, 2025; 1-for-60 reverse, May 23, 2024; 1-for-75 reverse, Jan 23, 2023; 1-for-3 reverse, Sep 8, 2021; 1-for-70 reverse, Jun 7, 2019; 1-for-70 reverse, Jun 3, 2019; 1-for-15 reverse, Jun 1, 2018; 1-for-15 reverse, May 18, 2018
- SEC CIK
- 1585608
- CUSIP
- 47010C854
- ISIN
- US47010C8543
- LEI
- 549300DJ0Q0D9TVY5O19
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Lisa A. Conte | See Remarks, Director | 29,258 |
| Jonathan S. Wolin | See Remarks | 11,938 |
| Steven R. King | See Remarks | 11,885 |
| Carol R. Lizak | Chief Financial Officer | 11,912 |
| Pravin R. Chaturvedi | Chief Scientific Officer | 11,938 |
| John Micek | Director | 7,430 |
| Anula Jayasuriya | Director | 5,916 |
| James J. Bochnowski | Director | 188,033 |
| Jonathan B. Siegel | Director | 7,482 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Lisa Conte | $705.68K | $548.78K | $508.60K | $0 | – |
| FY2024 Lisa Conte | $875.32K | $857.27K | $578.61K | $0 | – |
| FY2023 Lisa Conte | $815.85K | $611.19K | $560.49K | $2 | – |
| FY2022 Lisa Conte | $1.09M | $491.16K | $592.10K | $4 | – |
| FY2021 Lisa Conte | $3.06M | $1.36M | $929.29K | $43 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had forty-seven employees.”
Corporate history
Events identified from SEC filings